Fresenius Settles With Johnson & Johnson to Market Stelara Alternative
By David Sachs
Pharmaceutical companies Fresenius Kabi and Formycon have reached a settlement with Johnson & Johnson to commercialize a Crohn's Disease drug in Europe and Canada.
Fresenius said Monday that the terms of the settlement for the drug, which mirrors Johnson & Johnson's trademarked Stelara, are confidential. Known as FYB202, the treatment also aids people with plaque psoriasis and ulcerative colitis, and is awaiting approval from regulators.
The settlement follows a similar one with Johnson & Johnson in the U.S. context. Fresenius Kabi and Formycon have had a license agreement in place since last year for marketing the drug after its approval, Fresenius said.
Johnson & Johnson did not immediately respond to a request for comment.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
March 18, 2024 05:51 ET (09:51 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks